|
|
|
|
| LEADER |
00000cam a2200000Ki 4500 |
| 001 |
11655036 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
180521s2018 ne o 000 0 eng d |
| 005 |
20240709185054.4 |
| 019 |
|
|
|a 1037293210
|a 1037807428
|a 1041882079
|
| 020 |
|
|
|a 9780323401135
|q (electronic bk.)
|
| 020 |
|
|
|a 0323401139
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323400169
|
| 020 |
|
|
|z 0323400167
|
| 035 |
|
|
|a (OCoLC)1036986100
|z (OCoLC)1037293210
|z (OCoLC)1037807428
|z (OCoLC)1041882079
|
| 035 |
|
9 |
|a (OCLCCM-CC)1036986100
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d YDX
|d EBLCP
|d OPELS
|d OCLCF
|d CASUM
|
| 049 |
|
|
|a MAIN
|
| 050 |
|
4 |
|a R857.N34
|
| 072 |
|
7 |
|a HEA
|x 012000
|2 bisacsh
|
| 072 |
|
7 |
|a HEA
|x 020000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 004000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 101000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 109000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 029000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 040000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 092000
|2 bisacsh
|
| 245 |
0 |
0 |
|a Emerging Nanotechnologies in Immunology :
|b The Design, Applications and Toxicology of Nanopharmaceuticals and Nanovaccines /
|c edited by Ranjita Shegokar, Eliana B. Souto.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c 2018.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/c
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/cr
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed May 23, 2018).
|
| 505 |
0 |
|
|a Front Cover; Emerging Nanotechnologies in Immunology; Copyright Page; Contents; List of Contributors; Biography; Preface; Key Features; 1 Nanopharmaceuticals in immunology: What's new in research?; 1.1 Introduction; 1.2 Application of Nanopharmaceuticals for Disease Treatment; 1.3 Evolution of Nanopharmaceuticals for Disease Treatment; 1.3.1 Cancer; 1.3.2 Immunotherapy; 1.3.3 Vaccines; 1.3.4 HIV/AIDS; 1.3.5 Tuberculosis and Malaria; 1.4 Conclusion; References; 2 Skin delivery of antimicrobial peptides; Abbreviations; 2.1 Introduction; 2.2 AMPs -- Chemistry, Antimicrobial and Antitumor Effects
|
| 505 |
8 |
|
|a 2.3 Human AMPs and Proteins2.3.1 Defensins; 2.3.2 Cathelicidins; 2.3.3 Psoriasin; 2.4 AMPs From Non-human Vertebrates and From Invertebrates; 2.4.1 Magainins and Temporins - AMPs From Frogs; 2.4.2 AMPs From Insects; 2.5 AMPs Regulate Homeostasis in Healthy and Diseased Skin; 2.6 Atopic Dermatitis; 2.6.1 Atopic Dermatitis and the AMPs; 2.6.2 Reconstructed Atopic Skin - AMPs and Bacterial Growth; 2.7 Psoriasis; 2.8 Acne; 2.9 Wound Healing/Keloid Formation; 2.10 Topical Use of AMPs; 2.11 Nanoparticle-Enhanced Peptide Penetration Into the Skin; 2.12 Penetration Enhancers for Protein Delivery
|
| 505 |
8 |
|
|a 2.13 Nanoparticle Enforced Peptide Effects2.13.1 Antibacterial Effects; 2.13.2 Nanoparticles for Improved Antipsoriatic Therapy; 2.14 Conclusion; References; Further Reading; 3 Skin penetration of nanoparticles; 3.1 Introduction; 3.2 Skin Structure and Function; 3.2.1 Skin Structure; 3.2.1.1 Epidermis; 3.2.1.2 Dermis; 3.2.1.3 Hypodermis (subcutis); 3.2.2 Derivative Structure of the Skin; 3.2.2.1 Hair; 3.2.2.2 Nails; 3.2.2.3 Sebaceous glands; 3.2.2.4 Sweat glands; 3.3 Skin Functions; 3.3.1 Mechanism of Skin Penetration; 3.3.1.1 Transappendageal route; 3.3.1.2 Transepidermal route
|
| 505 |
8 |
|
|a 3.3.1.3 Translocation3.4 Sources of NPs; 3.4.1 Significance of Skin Penetration Studies of NPs; 3.4.1.1 Designing novel topical and transdermal nanocarriers and biomedical diagnostic agents; 3.4.1.2 Understanding NPs health hazards; 3.4.2 Factors Affecting Skin Penetration of NPs; 3.4.2.1 Physicochemical properties of the penetrant; 3.4.2.1.1 Penetrant formulation; 3.4.2.1.2 Size and surface properties of penetrant; 3.4.2.1.3 Penetrant surface polarity; 3.4.2.1.4 Penetrant shape; 3.4.2.2 Vehicle effects; 3.4.2.2.1 Microemulsions; 3.4.2.2.2 Nanoemulsions
|
| 505 |
8 |
|
|a 3.4.2.2.3 Solid Lipid NPs and Nanostructured Lipid Carriers3.4.2.2.4 Liposomes; 3.4.2.2.5 Niosomes; 3.4.2.2.6 Transfersomes and ethosomes; 3.4.2.3 Surface area, dose, duration, and frequency of exposure; 3.4.2.4 Distribution; 3.4.2.5 Subanatomical pathways (skin appendages); 3.4.2.6 Skin surface condition; 3.4.2.6.1 Skin health and integrity; 3.4.2.6.2 Hydration; 3.4.2.6.3 Occlusion; 3.4.2.6.4 Temperature; 3.4.2.6.5 Other parameters; 3.4.2.7 Additional factors of skin penetration and permeation; 3.4.2.7.1 Different body regions and hair follicle volume and distribution; 3.4.2.7.2 Flexed skin
|
| 520 |
|
|
|a Emerging Nanotechnologies in Immunology: The Design, Applications and Toxicology of Nanopharmaceuticals and Nanovaccines aims to deliver a systematic and comprehensive review of data concerning the nature of interaction and nano-related risks between the nanopharmaceuticals currently in the pipeline of S&T development for skin, ocular and nasal drug delivery, including absorption, toxicity, and the ability to distribute after systemic exposure. The book's contributors address a representative set of the broad spectrum of nanopharmaceutics presently being used, including cationic lipid nanoparticles, polymeric PLGA, PLA nanoparticles, biomacromolecules-based nanoparticles, and other scaffolds tissue-engineered skin substitutes. In addition, regulation and risk are also covered since the safety of these nanopharmaceuticals still represents a barrier to their wide and innovative use.
|
| 650 |
|
0 |
|a Nanotechnology.
|0 http://id.loc.gov/authorities/subjects/sh91001490
|
| 650 |
|
0 |
|a Immunology
|x Technique.
|0 http://id.loc.gov/authorities/subjects/sh85064581
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Holism.
|2 bisacsh
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Reference.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Alternative Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Atlases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Essays.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Family & General Practice.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Holistic Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Osteopathy.
|2 bisacsh
|
| 650 |
|
7 |
|a Immunology
|x Technique.
|2 fast
|0 http://id.worldcat.org/fast/fst00968026
|
| 650 |
|
7 |
|a Nanotechnology.
|2 fast
|0 http://id.worldcat.org/fast/fst01032639
|
| 650 |
1 |
2 |
|a Nanomedicine
|x methods.
|0 http://id.nlm.nih.gov/mesh/D050997Q000379
|
| 650 |
1 |
2 |
|a Nanotechnology
|x methods.
|0 http://id.nlm.nih.gov/mesh/D036103Q000379
|
| 650 |
2 |
2 |
|a Nanostructures.
|0 http://id.nlm.nih.gov/mesh/D049329
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Shegokar, Ranjita,
|e editor.
|
| 700 |
1 |
|
|a Souto, Eliana B.,
|e editor.
|0 http://id.loc.gov/authorities/names/no2011155688
|
| 776 |
0 |
8 |
|i Print version:
|z 0323400167
|z 9780323400169
|w (OCoLC)1012344776
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i dc33e0a8-d0a0-5756-b0da-5b6b1cfb07f3
|s b02befce-3ffa-5749-b32b-db9b0c1dc392
|
| 928 |
|
|
|t Library of Congress classification
|a R857.N34
|l Online
|c UC-FullText
|u https://www.sciencedirect.com/science/book/9780323400169
|z Elsevier
|g ebooks
|i 11058408
|
